US Edition
Neurocrine Biosciences Highlights INGREZZA’s Impact on Quality of Life in Tardive Dyskinesia Patients at ISPOR 2025
Summary by healtheconomics.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Neurocrine Biosciences Highlights INGREZZA’s Impact on Quality of Life in Tardive Dyskinesia Patients at ISPOR 2025
Neurocrine Biosciences presented new data at ISPOR 2025 from its Phase 4 KINECT-PRO™ study, demonstrating that INGREZZA® (valbenazine) significantly improves the physical, social, and emotional impacts of tardive dyskinesia (TD) in patients, regardless of TD severity or underlying psychiatric condition. This study is the first to assess the patient-reported impact of a vesicular monoamine transporter 2 inhibitor on TD using multiple clinically v…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
